GlassScriptPhysician profile
Prasad Balkrishna Bichu
NPI 1679675748
$2,175.54
in general payments reported to CMS, 2019-2025
21 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $93.87 · 2021: $133 · 2022: $208 · 2023: $592 · 2024: $197 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,296 · Education: $14.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,296.49 |
| Education | $14.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $317.35 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $300.49 | 2019-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $225.26 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $189.74 | 2023-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $185.01 | 2019-2025 | |
| Fresenius USA Marketing, INC. | $177.75 | 2019-2025 | Velphoro, Velphoro |
| Nxstage Medical, INC. | $137.17 | 2021-2022 | |
| Aurinia Pharma U.S., INC. | $119.82 | 2023-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.10 | 2025 | Jardiance |
| Akebia Therapeutics INC | $82.78 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $45.41 | 2022 | |
| Mallinckrodt Enterprises LLC | $44.62 | 2019 | |
| Vifor Pharma, INC. | $42.27 | 2020-2022 | |
| Amgen INC. | $34.26 | 2024-2025 | Tavneos, Procysbi |
| Ardelyx, INC. | $30.24 | 2024 | Ibsrela |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $29.43 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $29.33 | 2024 | |
| Travere Therapeutics, INC. | $27.71 | 2025 | Filspari |
| Ultragenyx Pharmaceutical INC. | $24.33 | 2023 | |
| Apellis Pharmaceuticals, INC. | $24.01 | 2025 | Empaveli |
| Horizon Therapeutics Plc | $18.46 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prasad Bichu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.